Coronary disease & ACSCohort study
Validation of a high bleeding risk definition in cancer patients undergoing percutaneous coronary intervention
- Cohort study (validation of a bleeding risk definition)
- single-centre
- consecutive patients
Authors' conclusion
An adapted version of the ARC-HBR criteria, in which cancer is not a major criterion, effectively delineates cancer patients undergoing PCI who are at HBR. Cancer patients at HBR according to this definition also exhibited a higher mortality risk.
Study context
- Population
- Patients with active or remission cancer undergoing percutaneous coronary intervention (PCI), Mount Sinai Hospital (New York, USA), 2012–2022
- Participants
- 2,007 patients
- Exposure
- High Bleeding Risk (HBR) vs non-HBR by adapted ARC-HBR criteria
- HBRn = 1,142
- Outcome
- Composite of:
- Periprocedural in-hospital
- Post-discharge bleeding
- Follow-up
- 1 year
Main finding
Bleeding
Adjusted hazard ratio
2.36
95% CI 1.57–3.53
P < 0.001
By group
HBR
10.9
%
non-HBR
3.9%
HBR vs non-HBR
adjusted HR 2.36 (95% CI 1.57–3.53); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HBR | non-HBR | adjusted HR (95% CI) | P value | |
|---|---|---|---|---|---|
| MACCE (death, MI or stroke) (key secondary) | 11.0% | 3.2% | 2.78 (1.72–4.47) | P < 0.001 | |
| Death | 8.8% | 2.2% | 3.28 (1.87–5.77) | P < 0.001 | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Moderate to severe anaemia (most prevalent major HBR criterion)
- Prevalence
- 35%
Original publication
Validation of a high bleeding risk definition in cancer patients undergoing percutaneous coronary intervention. Eur J Prev Cardiol. Published 21 December 2024. doi:10.1093/eurjpc/zwae399
Summarised from the published abstract; every number is checked against it